Leerink Partnrs Has Positive Outlook of Zura Bio Q1 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for Zura Bio in a research note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.13) per share for the quarter, up from their prior estimate of ($0.15). The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio's Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.

Other equities analysts have also recently issued reports about the company. Guggenheim reiterated a "buy" rating and set a $15.00 price target on shares of Zura Bio in a report on Wednesday, March 26th. Chardan Capital dropped their target price on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, March 26th. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright reaffirmed a "neutral" rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Finally, Oppenheimer restated an "outperform" rating and set a $19.00 target price (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $15.00.

Remove Ads

Zura Bio Price Performance

Zura Bio stock traded up $0.02 during trading on Friday, reaching $1.29. 353,030 shares of the company were exchanged, compared to its average volume of 377,507. The stock's 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $2.72. Zura Bio has a 52-week low of $1.07 and a 52-week high of $6.35. The company has a market capitalization of $83.90 million, a P/E ratio of -2.42 and a beta of 0.06.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently bought and sold shares of ZURA. SG Americas Securities LLC raised its holdings in shares of Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock worth $58,000 after purchasing an additional 7,828 shares during the period. Wells Fargo & Company MN raised its position in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after purchasing an additional 9,379 shares during the period. Bank of America Corp DE boosted its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock valued at $103,000 after purchasing an additional 9,966 shares during the last quarter. Rhumbline Advisers increased its holdings in Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock valued at $94,000 after buying an additional 10,231 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in Zura Bio in the fourth quarter worth $27,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.